BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-25 out of over 1000 found
  Current Search:  new: 91732, drug: 44146, applic: 8841, nda: 1193     

HTML
100%
BiomedReports: FDA Calendar Updates for Eisai (OTC:ESALY), King Pharma (NYSE:KG), Myriad Pharma (NASDAQ:MYRX)
(M2 PRESSWIRE via COMTEX) -- BioMedReports.

Com, the news portal covering the biomedical sector that delivers financial and investment intelligence to a community of highly informed investors has new updates to it's database of...

TMC Net:  Jul 3 2009 4:19PM
Matching: new drug applic nda
Find similar documents
HTML
100%
King Pharmaceuticals Inc announces receipt of complete response letter from FDA for Acurox
(M2 EQUITYBITES via COMTEX) -- KG | Quote | Chart | News | PowerRating -- Acura Pharmaceuticals Inc (Nasdaq:ACUR) and King Pharmaceuticals Inc (NYSE:KG) declared on Thursday that the pharmaceutical companies have received a complete...
TradingMarkets:  Jul 3 2009 3:43PM
Matching: new drug applic nda
Find similar documents
HTML
100%
Current Status Of The Development Programs Of New Indications And Formulations For Aricept(R) For Enhancing Pa
Eisai Co., Ltd.

(Headquarters: Tokyo, President & CEO: Haruo Naito, 'Eisai') and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical...

Medical News Today:  Jul 3 2009 11:41AM
Matching: new drug applic nda
Find similar documents
HTML
100%
Eisai to file new Aricept formulation, wants out of Pfizer pact
Eisai is looking to file a new formulation of Aricept in the next couple of months and is confident about terminating its collaboration with Pfizer, the Japanese drugmakers marketing partner for the Alzheimer's disease blockbuster.
Pharma Times:  Jul 3 2009 1:58PM
Matching: new drug applic nda
Find similar documents
HTML
100%
Acura And King Receive FDA Complete Response Letter Regarding Acurox(R)
Acura Pharmaceuticals, Inc.

(Nasdaq: ACUR) and King Pharmaceuticals, Inc.

(NYSE: KG) announced today that the U.S.

Food and Drug Administration (FDA) has issued a Complete Response Letter regarding the New Drug ...

Medical News Today:  Jul 3 2009 11:30AM
Matching: new drug applic nda
Find similar documents
HTML
100%
CombinatoRx and Neuromed Sign Merger Agreement
- Merger to Create a Sustainable Biotechnology Company: Brings Together Significant Product Assets, Unique Discovery Capabilities and Financial Resources - CAMBRIDGE, MA and VANCOUVER, BC, July 2 /PRNewswire/ - CombinatoRx, Incorporated and...
KSLA:  Jul 3 2009 12:30AM
Matching: new drug applic nda
Find similar documents
HTML
100%
POZEN Submits New Drug Application For VIMOVO' (PN 400)
POZEN Inc.

(NASDAQ:POZN), announced the submission of a New Drug Application (NDA) to the U.S.

Food and Drug Administration (FDA) for the marketing approval of VIMOVO (PN 400), the combination of enteric...

Medical News Today:  Jul 2 2009 5:35PM
Matching: new drug applic nda
Find similar documents
HTML
100%
POZEN Submits New Drug Application For VIMOVO (PN 400)
POZEN Inc.

(NASDAQ:POZN), announced the submission of a New Drug Application (NDA) to the U.S.

Food and Drug Administration (FDA) for the marketing approval of VIMOVO (PN 400), the combination of enteric...

Medical News Today:  Jul 2 2009 12:07PM
Matching: new drug applic nda
Find similar documents
HTML
100%
Acura Pharma, King Pharma Receive FDA Complete Response Letter Regarding NDA For Acurox - Quick Facts
AM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Acura Pharmaceuticals, Inc.

(ACUR: News ) and King Pharmaceuticals, Inc.

(KG: News ) announced that the U.S.

Food and Drug Administration has issued a...

RTTNews.com:  Jul 2 2009 11:28AM
Matching: new drug applic nda
Find similar documents
HTML
100%
Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Pa
TOKYO and WOODCLIFF LAKE, N.J.

, July 2 /PRNewswire/ -- Eisai Co., Ltd.

(Headquarters: Tokyo , President & CEO: Haruo Naito 1.

Sustained Release Tablets Eisai has completed a Phase III study of Aricept 23 mg sustained release (SR)...

NewsBlaze:  Jul 2 2009 12:26PM
Matching: new drug applic nda
Find similar documents
HTML
100%
Current Status of the Development Programs of New Indications and Formulations for Aricept for Enhancing Patie
TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Eisai Co., Ltd.

(Headquarters: Tokyo, President & CEO: Haruo Naito, 'Eisai') and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime...

Pharma Live:  Jul 2 2009 4:10PM
Matching: new drug applic nda
Find similar documents
HTML
100%
Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)
Companies mentioned in this article: King Pharmaceuticals, Inc.

PALATINE, Ill.

and BRISTOL, Tenn., July 2 /PRNewswire-FirstCall/ -- Acura Pharmaceuticals, Inc.

(Nasdaq: ACUR) and King Pharmaceuticals, Inc.

(NYSE: KG) announced today...

Freshnews.com:  Jul 2 2009 3:00PM
Matching: new drug applic nda
Find similar documents
HTML
100%
Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Pa
Companies mentioned in this article: Eisai Co., Ltd.

TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Eisai Co., Ltd.

(Headquarters: Tokyo, President & CEO: Haruo Naito, 'Eisai') and Eisai Corporation of North America ...

Freshnews.com:  Jul 2 2009 2:58PM
Matching: new drug applic nda
Find similar documents
HTML
100%
Photocure submits application for marketing approval for Hexvix in USA to the FDA
--Photocure announces today that a New Drug Application (NDA) has been submitted to the US Health Authorities (FDA) to obtain approval for Hexvix for use in the detection of papillary bladder cancer using fluorescence...
Pharma Live:  Jul 2 2009 7:22AM
Matching: new drug applic nda
Find similar documents
HTML
100%
Photocure submits application for marketing approval for Hexvix, in USA to the FDA
Photocure announces today that a New Drug Application (NDA) has been submitted to the US Health Authorities (FDA) to obtain approval for Hexvix for use in the detection of papillary bladder cancer using fluorescence...
Pharmacy Choice:  Jul 1 2009 11:45PM
Matching: new drug applic nda
Find similar documents
HTML
100%
PPD Confirms Takeda Receives FDA Complete Response For Alogliptin
PPD, Inc.

(NASDAQ: PPDI) today announced that Takeda Pharmaceutical Company Limited issued a news release reporting that Takeda Global Research & Development Center, Inc., its wholly-owned U.S.

subsidiary, has received a...

Pharmaceutical Online:  Jul 2 2009 4:52AM
Matching: new drug applic nda
Find similar documents
HTML
100%
CombinatoRx and Neuromed Sign Merger Agreement
- Merger to Create a Sustainable Biotechnology Company: Brings Together Significant Product Assets, Unique Discovery Capabilities and Financial Resources - CAMBRIDGE, MA and VANCOUVER, BC, July 2 /PRNewswire/ - CombinatoRx, Incorporated and...
KLFY:  Jul 2 2009 7:16PM
Matching: new drug applic nda
Find similar documents
HTML
100%
Acura (ACUR) & King Pharmaceuticals (KG) Receive Complete Response Letter From FDA for Acurox
Acura Pharmaceuticals, Inc.

(Nasdaq: ACUR) and King Pharmaceuticals, Inc.

(NYSE: KG) announced today that the U.S.

Food and Drug Administration (FDA) has issued a Complete Response Letter regarding the New Drug ...

Street Insider:  Jul 2 2009 1:24PM
Matching: new drug applic nda
Find similar documents
HTML
100%
CombinatoRx And Neuromed Sign Merger Agreement
CombinatoRx, Incorporated (NASDAQ: CRXX) and Neuromed Pharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced they have entered into a definitive merger agreement under which CombinatoRx and Neuromed will merge in...
Pharmaceutical Online:  Jul 2 2009 8:23AM
Matching: new drug applic nda
Find similar documents
HTML
68%
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals Inc., Palm, Inc. Everest Re, Ace Limited and M
ity Research highlights AMAG Pharmaceuticals Inc.

(Nasdaq: AMAG | Quote | Chart | News | PowerRating) as the Bull of the Day and Palm, Inc.

(Nasdaq: PALM | Quote | Chart | News | PowerRating) the Bear of the Day.

In...

TradingMarkets:  Jul 2 2009 9:56PM
Matching: new drug nda
Find similar documents
HTML
68%
FDA Calendar Updates: Repros, Discovery, Acorda, Human Genome Sciences
Below is a summary of updates to the , which includes a database of over 200 entries.

I originally created this calendar to track companies with pending new drug, biological agent, or medical device new product decisions...

Seeking Alpha:  Jul 2 2009 1:16PM
Matching: new drug nda
Find similar documents
HTML
68%
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals Inc., Palm, Inc. Everest Re, Ace Limited and M
http://www.profit.zacks.com/ CHICAGO--(Business Wire)-- Zacks Equity Research highlights AMAG Pharmaceuticals Inc.

(Nasdaq: AMAG) as the Bull of the Day and Palm, Inc.

(Nasdaq:PALM) the Bear of the Day.

In addition, Zacks Equity...

Reuters:  Jul 2 2009 9:30PM
Matching: new drug nda
Find similar documents
HTML
68%
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals Inc., Palm, Inc. Everest Re,
BusinessWire - Zacks Equity Research highlights AMAG Pharmaceuticals Inc.

(Nasdaq: AMAG) as the Bull of the Day and Palm, Inc.

(Nasdaq: PALM) the Bear of the Day.

In addition, Zacks Equity Research provides analysis on Everest Re (NYSE...

Forbes.com:  Jul 2 2009 9:29PM
Matching: new drug nda
Find similar documents
HTML
68%
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals
highlights AMAG Pharmaceuticals Inc.

(Nasdaq: AMAG) as the and Palm, Inc.

(Nasdaq:PALM) the.

In addition, provides analysis on Everest Re (NYSE:RE), Ace Limited (NYSE:ACE) and Montpelier (NYSE:MRH).

Full analysis of all these stocks...

Business Wire via MSN Money:  Jul 2 2009 9:20PM
Matching: new drug nda
Find similar documents
HTML
68%
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals Inc., Palm, Inc. Everest Re, Ace Limited and M
CHICAGO--(BUSINESS WIRE)-- highlights AMAG Pharmaceuticals Inc.

(Nasdaq: AMAG) as the and Palm, Inc.

(Nasdaq: PALM) the.

In addition, provides analysis on Everest Re (NYSE: RE), Ace Limited (NYSE: ACE) and Montpelier (NYSE: MRH).

Yahoo! Canada:  Jul 2 2009 9:18PM
Matching: new drug nda
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.